Combogesic IV consists of acetaminophen 1000mg and ibuprofen 300mg in a solution for IV infusion.
In a significant development for postoperative pain management, the FDA has given its approval for a non-opioid combination therapy. This marks a crucial step in addressing the need for effective and safer alternatives to opioid-based pain relief.
- The FDA-approved therapy is known as Combogesic IV, or Maxigesic IV outside the US.
- Combogesic IV is an intravenous formulation of acetaminophen (1000mg) and ibuprofen (300mg).
- The approval was backed by data from two phase 3 studies evaluating its effects on adults with postoperative pain.
- Results showed a faster onset of action and greater pain relief with Combogesic IV compared to ibuprofen IV or acetaminophen IV alone.
- Treatment with Combogesic IV was also associated with reduced opioid consumption.
- The therapy was found to be safe and well-tolerated in a safety study involving 232 patients undergoing general, orthopedic, or plastic surgery.
- Distribution of the product in US hospitals is expected to begin in early 2024.
“The greatest evil is physical pain.”
– Saint Augustine
More on Pain Management